

Hans-Ulrich Schildhaus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7112289/publications.pdf>

Version: 2024-02-01

55
papers

3,597
citations

304743

22
h-index

182427

51
g-index

55
all docs

55
docs citations

55
times ranked

6032
citing authors

#	ARTICLE	IF	CITATIONS
1	⁶⁸ Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸ Ga-FAPI PET Prospective Observational Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 89-95.	5.0	58
2	Reversible occlusion of the pulmonary vasculature by transarterial embolisation with degradable starch microspheres: preclinical assessment in a human isolated lung perfusion model. <i>European Radiology Experimental</i> , 2022, 6, 6.	3.4	0
3	Patterns of Tumor Infiltrating Lymphocytes in Adenoid Cystic Carcinoma of the Head and Neck. <i>Cancers</i> , 2022, 14, 1383.	3.7	5
4	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. <i>Lung Cancer</i> , 2022, 168, 10-20.	2.0	6
5	High-Throughput Profiling of Colorectal Cancer Liver Metastases Reveals Intra- and Inter-Patient Heterogeneity in the EGFR and WNT Pathways Associated with Clinical Outcome. <i>Cancers</i> , 2022, 14, 2084.	3.7	5
6	GenoType CM Direct [®] and VisionArray Myco [®] for the Rapid Identification of Mycobacteria from Clinical Specimens. <i>Journal of Clinical Medicine</i> , 2022, 11, 2404.	2.4	3
7	MCL1 as putative target in pancreaticoblastoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 265-272.	2.8	3
8	Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors [®] A Retrospective Multi-Center Registry Analysis. <i>Cancers</i> , 2022, 14, 3405.	3.7	4
9	Surgical Treatment for Primary Chest Wall Sarcoma: A Single-Institution Study. <i>Journal of Surgical Research</i> , 2021, 260, 149-154.	1.6	7
10	Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. <i>Cancer Discovery</i> , 2021, 11, 108-125.	9.4	47
11	BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. <i>European Journal of Cancer</i> , 2021, 149, 211-221.	2.8	9
12	Initial clinical experience with ⁹⁰ Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262468.	5.0	64
13	Frequency of actionable molecular drivers in lung cancer patients with precocious brain metastases. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106841.	1.4	0
14	Localized Angiosarcoma, Not One Disease: A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and Etiology. <i>Sarcoma</i> , 2021, 2021, 1-10.	1.3	6
15	HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2. <i>European Journal of Cancer</i> , 2021, 159, 16-23.	2.8	23
16	Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation. <i>Lung Cancer</i> , 2020, 139, 165-168.	2.0	4
17	Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. <i>Translational Lung Cancer Research</i> , 2020, 9, 603-616.	2.8	21
18	ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 149, 10-16.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Multimodality treatment including surgery for primary pulmonary sarcoma: Size does matter. <i>Journal of Surgical Oncology</i> , 2020, 122, 506-514.	1.7	8
20	Pleuropulmonary Blastoma Misinterpreted as Spontaneous Pneumothorax in an Infant. <i>Annals of Thoracic Surgery</i> , 2020, 110, e79.	1.3	5
21	Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancerâ€”The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol. <i>Diagnostics</i> , 2020, 10, 459.	2.6	3
22	Crizotinib in <i>ROS1</i> and <i>MET</i> Deregulated NSCLCâ€”Letter. <i>Clinical Cancer Research</i> , 2020, 26, 1774-1774.	7.0	3
23	KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors â€” TORC1/2 Inhibition as Salvage Strategy. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1985-1996.	4.1	22
24	Automated density-based counting of FISH amplification signals for HER2 status assessment. <i>Computer Methods and Programs in Biomedicine</i> , 2019, 173, 77-85.	4.7	14
25	Predictive Biomarkers and Targeted Therapies in Sarcomas. , 2019, , 475-492.		0
26	CIC fusion-positive sarcoma of the spermatic cord. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 253-257.	2.8	4
27	Dramatic Response of a PD-L1â€”Positive Advanced Angiosarcoma of the Scalp to Pembrolizumab. <i>JCO Precision Oncology</i> , 2018, 2, 1-7.	3.0	16
28	8. Molekularpathologie. , 2018, , 303-350.		0
29	Comparative proteomics reveals a diagnostic signature for pulmonary head&neck cancerâ€”metastasis. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	41
30	Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFR α wild-type GISTs are rare events. <i>Human Pathology</i> , 2017, 62, 206-214.	2.0	50
31	METâ€”GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 7084-7096.	7.0	12
32	Spindle cell embryonal rhabdomyosarcoma of the prostate in an adult patient â€” case report and review of clinicopathological features. <i>Diagnostic Pathology</i> , 2016, 11, 56.	2.0	8
33	HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 59-71.	3.0	9
34	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 4837-4847.	7.0	223
35	Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis. <i>Diagnostic Pathology</i> , 2015, 10, 118.	2.0	27
36	MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas. <i>PLoS ONE</i> , 2015, 10, e0120079.	2.5	18

#	ARTICLE	IF	CITATIONS
37	miRNAâ€221 and miRNAâ€222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. <i>Molecular Oncology</i> , 2015, 9, 1421-1433.	4.6	71
38	Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. <i>BMC Cancer</i> , 2015, 15, 291.	2.6	7
39	<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung. <i>Clinical Cancer Research</i> , 2015, 21, 907-915.	7.0	155
40	c-myc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia. <i>Oncotarget</i> , 2015, 6, 825-835.	1.8	22
41	Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. <i>Clinical Cancer Research</i> , 2014, 20, 6105-6116.	7.0	129
42	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. <i>BMC Cancer</i> , 2014, 14, 13.	2.6	220
43	High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors. <i>Human Pathology</i> , 2014, 45, 573-582.	2.0	13
44	Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. <i>Modern Pathology</i> , 2014, 27, 214-221.	5.5	90
45	Î²â€Catenin (<i>CTNNB1</i>) mutations and clinicopathological features of mesenteric desmoidâ€™type fibromatosis. <i>Histopathology</i> , 2013, 62, 294-304.	2.9	93
46	Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung. <i>Modern Pathology</i> , 2013, 26, 1468-1477.	5.5	32
47	Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1648-1659.	3.7	39
48	A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). <i>Modern Pathology</i> , 2013, 26, 1004-1012.	5.5	51
49	Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. <i>Modern Pathology</i> , 2012, 25, 1473-1480.	5.5	118
50	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	21.4	1,186
51	Activating <i>PDGFRA</i> mutations in inflammatory fibroid polyps occur in exons 12, 14 and 18 and are associated with tumour localization. <i>Histopathology</i> , 2012, 61, 59-68.	2.9	82
52	qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL. <i>BMC Molecular Biology</i> , 2010, 11, 100.	3.0	14
53	Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. <i>BMC Medical Genetics</i> , 2010, 11, 106.	2.1	31
54	Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1. <i>Clinical Cancer Research</i> , 2008, 14, 4550-4555.	7.0	158

#	ARTICLE	IF	CITATIONS
55	Polyclonal Evolution of Multiple Secondary <i>KIT</i> Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2006, 12, 1743-1749.	7.0	351